BSE filing, NSE: RELIGARE. Summary written from the filing by ALFA Finder's alert engine.
Religare Enterprises Ltd: key numbers
- Share price
- ₹212.35
- Market cap
- ₹7,321 Cr
- Revenue (annual)
- ₹8,459 Cr
- Net profit (annual)
- ₹85.96 Cr
- P/E (TTM)
- 315.6×Sector 19.8×
- Promoter holding
- 31.26%+0.70% QoQ
- FII holding
- 9.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Religare Enterprises Ltd
All →Religare Enterprises Debt & Borrowing: ₹150 Cr
Care Health Insurance, a material subsidiary of Religare, allotted listed subordinated debentures worth ₹150 Crore at a 10.50% coupon. The debentures mature in 2036, callable after five years.
- Value
- ₹150.0 Cr
Religare Enterprises Management Change
Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.
Religare Enterprises Other Announcement
Religare Enterprises has filed its quarterly shareholding pattern for the period ending September 30, 2026, as per SEBI Regulation 31(1)(b).
Religare Enterprises Employee Stock Options
Religare Enterprises allotted 22,000 equity shares upon exercise of employee stock options. This allotment increases the company's issued and paid-up equity capital.
Religare Enterprises Management Change
Religare disclosed Mr. Gaurav Sharma as CTO of subsidiary Religare Finvest, effective October 6, 2026. He brings ~30 years of fintech experience from IIFL and L&T Financial.
Religare Enterprises Annual General Meeting
Religare Enterprises Limited held its 42nd Annual General Meeting on September 24, 2026, where members adopted financial statements and approved the re-designation of Mr. Arjun Lamba.
Other acquisition announcements
All →Kalpataru Acquisition Worth ₹52.55 Cr
Kalpataru's subsidiary KPL approved acquiring 16.67% of step-down subsidiaries AREPL and AREDPL for ₹52.55 Crore. This makes them wholly owned, giving Kalpataru 100% of Kalpataru Parkcity project cash flows at Thane.
- Value
- ₹52.55 Cr
- Execution
- 60 days, subject to receipt of requisite approvals
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Arvaya Healthcare Acquisition
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Affle 3I Acquisition Worth ₹3,990 Cr
Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.
- Value
- ₹3,990 Cr
- Execution
- Expected to close in early 2027